Drug Development

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

By out-licensing its early-stage hypophosphatasia drug, 1cBio secured non-dilutive capital to fund its proprietary oncology pipeline without the usual risks.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

The clinical-stage biotech's public debut tests investor appetite for immunology as it funds a novel Treg pipeline into 2029.

Following its 2024 Sanofi spin-off, Inhibrx Biosciences is preparing to unveil pivotal cancer trial data that could validate its multivalent protein platform.

As the National Academy of Medicine's $1.5M competition concludes, a novel biologic targeting muscle loss challenges how we treat human aging.

Trevi Therapeutics heads to CHEST 2026 with compelling patient-reported outcomes for its IPF chronic cough drug, aiming to fill a massive clinical void.

Immuron’s Phase 2 Travelan trial missed its primary endpoint, but a 71% drop in antibiotic use has the Pentagon and microbiome experts paying close attention.

After a high-profile Phase 2 trial failure in pulmonary fibrosis, Syndax narrows its strategic focus to maximize its established cGVHD partnership with Incyte.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

For decades, severe acne treatments forced patients into a maze of antibiotics and harsh side effects. A new drug might finally change the system.

With new Phase 3 data for inactive thyroid eye disease, Innovent Biologics is solidifying a domestic moat against foreign biotech rivals in China.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Jack Patterson examines how new off-the-shelf CAR T-cell therapy and optimized monoclonal antibodies could disrupt the multiple sclerosis treatment paradigm.

As regulatory demands surge, the EVERSANA and Pulse Infoframe alliance signals a vital shift from siloed trials to continuous real-world data pipelines.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Oncodesign Precision Medicine is advancing its LRRK2 inhibitor OPM-201 toward Phase 1b. Here is how strategic repatriation and non-dilutive funding are paving the commercial pathway.

The Food Allergy Science Initiative is shifting from basic research to biotech incubator, launching a $10M accelerator to turn academic discoveries into drugs.

As geopolitical headwinds stall international research, a $12M philanthropic injection is uniting global experts to hack cancer's most elusive mechanisms.